Phagos
About
Phagos is a biotechnology company focused on developing novel bacteriophage therapies to address the growing threat of antibiotic-resistant bacteria. Their approach leverages the natural predators of bacteria, phages, to create targeted and effective treatments for infections that are no longer responsive to conventional antibiotics.
Key facts
At-a-glance profile data
- Website
- phagos.com
- Headquarters
- Boston, United States
- Founded
- 2021
- Employees
- 74
- Total funding
- $29M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 8 Oct 2025 | Series A | $27M | Sofinnova Partners, AdBio Partners |
| 1 May 2023 | Undisclosed round | $2M | - |
Tech stack
Detected on phagos.com, last scanned 24 Sept 2026. Run your own scan
- Analytics
- Google Analytics 4, Microsoft Clarity
- CMS / Builders
- Framer
- Email provider
- Google Workspace
Add first review
Frequently asked
How much funding has Phagos raised?
Phagos has raised a total of $29M in funding. The most recent round on record is Series A.
How many employees does Phagos have?
Phagos has approximately 74 people on record.